Medicaid, the Drug Pricing Program and FDA are subtly connected, which brings them all passively under the DSCSA regulatory ambit. It is important to note here that what links all of them are the supply chain stakeholders, precisely manufacturers and contract pharmacies functioning under the DSCSA law.
The lack of T3 information is one of the major concerns that riddles the supply chain, which deals with both types of drugs. So, how can they be authenticated? The asset attached below will answer all of that and more:
Are there cost-effective solutions to enable seamless handling of these independent drugs in the same DSCSA compliance-approved supply chain?
How can contract pharmacies and manufacturers ensure that only DSCSA-approved and not counterfeit products are reaching the benefactors at the end of the supply chain?
Is it possible without the transaction information?
Is there a cost-effective way to store such information independently without spending too much (if the stakeholder desires to do so)?
While being your knowledge partner and compliance consultant for all things 340B, TrackTraceRX promises of cost-effective and efficient solutions that can handle both mainstream and Pricing Program consignments. The solutions we offer include:
AR-enabled multiscanners: For real-time inputs on the status of drugs that empower stakeholders to conduct contact-less screening under the program.
Traceability Suites: Ready or not! It stores the T3 information no matter what, to make you self-reliant and audit-ready at any point in time.
Cloud-based master database: Flexible and expansive, the data stays secured and within your reach. Visibility of drugs enhances as you stay connected with the networked manufacturers.
To explore more on how the program operates, who are the beneficiaries, how do the stakeholders benefit and the eligibility criteria to participate in program, download the asset provided below. You can also get the detailed technological know-hows on the solutions we provide to handle 340B drugs alongside the mainstream drugs seamlessly.